Two Generations of Light/Never-Smokers With Advanced Adenocarcinoma of the Lung with Durable Responses to Erlotinib Nathan A. Pennell, MD, PhD, Lihong.

Slides:

Advertisements

Similar presentations

Lung Adenocarcinoma with Ipsilateral Breast Metastasis: A Simple Coincidence? Hsu-Ching Huang, MD, Jen-Fan Hang, MD, Mei-Han Wu, MD, Teh-Ying Chou, MD,

Advertisements

Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry Yan.

Primary Small Cell Carcinoma of the Esophagus Jima Lv, MD, Jun Liang, MD, Jinwan Wang, MD, Luhua Wang, MD, Jie He, MD, Zefen Xiao, MD, Weibo Yin, MD Journal.

Kazuma Nagata, MD, Reiko Kaji, MD, Keisuke Tomii, MD

A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21 Marie Florescu,

Inflammatory Myofibroblastic Tumor of the Left Main Stem Bronchus

Successful Osimertinib Rechallenge in a Patient with T790M-Mutant Non–Small Cell Lung Cancer after Osimertinib-Induced Interstitial Lung Disease Eisaku.

Chia-Lin Hsu, MD, Kuan-Yu Chen, MD, PhD Journal of Thoracic Oncology

Leptomeningeal and Medullary Response to Second-Line Erlotinib in Lung Adenocarcinoma Mathilde Wagner, MD, Benjamin Besse, MD, Corinne Balleyguier, MD,

James B. Yu, MD, Lynn D. Wilson, MD, MPH, Frank C. Detterbeck, MD

EGFR and KRAS Mutations in Triple-Mutated Lung Cancer

Y-L Chang, MD, C-T Wu, MD, Y-C Lee, MD, PhD

Waleed Brinjikji, MD, Jennifer M. Boland Froemming, MD, William P

Long-Term Follow-up of Small Pulmonary Ground-Glass Nodules Stable for 3 Years: Implications of the Proper Follow-up Period and Risk Factors for Subsequent.

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21 Marie Florescu,

Long-Lasting Complete Remission with Tyrosine Kinase Inhibitor in Bronchioloalveolar Carcinoma with a so far Unknown EGFR Mutation Vienna Ludovini, PhD,

Electronic Updates for JTO Readers

The Moth-Eaten Lung Journal of Thoracic Oncology

Successful Crizotinib Retreatment after Crizotinib-Induced Interstitial Lung Disease Satoru Yanagisawa, MD, PhD, Akira Inoue, MD, PhD, Akira Koarai, MD,

Coexistence of the BRAF Mutation and EGFR Exon 20 Insertion in a Patient with Lung Adenocarcinoma Lih-Chyun Chang, MD, Kuan-Yu Chen, MD, PhD, Jin-Yuan.

Atypical Pleuropulmonary Tuberculosis Mimicking a Malignant Disease

Frank Detterbeck, MD Journal of Thoracic Oncology

Ziad Thotathil, MD, FRCR, Jeremy Long, FRACP

Successful Treatment with Erlotinib after Gefitinib-Induced Severe Interstitial Lung Disease Masayuki Takeda, MD, PhD, Isamu Okamoto, MD, PhD, Chihiro.

How Long Should Small Lung Lesions of Ground-Glass Opacity be Followed? Yoshihisa Kobayashi, MD, Takayuki Fukui, MD, Simon Ito, MD, Noriyasu Usami, MD,

Effective Treatment with Icotinib in Primary Adenoid Cystic Carcinoma of the Lung with Liver Metastasis Zhengbo Song, MD, Wei Wu, MD, Yiping Zhang, MD

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Disease Flare After Treatment Discontinuation in a Patient With EML4-ALK Lung Cancer and Acquired Resistance to Crizotinib Oana Pop, MD, Augustin Pirvu,

Massive Bronchogenic Cyst

Are There Imaging Characteristics Associated with Epidermal Growth Factor Receptor and KRAS Mutations in Patients with Adenocarcinoma of the Lung with.

Coexistence of Tyrosine Kinase Inhibitor-Sensitizing and Resistant EGFR Mutations in an Untreated Lung Adenocarcinoma Patient and Response to Erlotinib

Elderly Former Smoker with HRAS Mutant Non–Small-Cell Lung Cancer

RET-Rearranged Lung Adenocarcinomas with Lymphangitic Spread, Psammoma Bodies, and Clinical Responses to Cabozantinib Sanjay Mukhopadhyay, MD, Nathan.

Frequency of Lymph Node Metastasis According to the Size of Tumors in Resected Pulmonary Adenocarcinoma with a Size of 30 mm or Smaller Yangki Seok,

Nivolumab-Induced Acute Diabetes Mellitus and Hypophysitis in a Patient with Advanced Pulmonary Pleomorphic Carcinoma with a Prolonged Tumor Response

Elizabeth Cathcart-Rake, MD, Ariel Lopez-Chavez, MD, MS

The Role of Surgery in the Management of Primary Thymic Mucosa-associated Lymphoid Tissue (MALT) Lymphoma Kimihiro Shimizu, MD, PhD, Izumi Takeyoshi,

Jennifer L. Dallas, MD, Michael A. Jantz, MD, Judith L

A Case of Nontuberculous Mycobacteria Highly Suspected as Lung Cancer Invading the Aortic Arch Tadashi Umehara, MD, Masaya Aoki, MD, PhD, Aya Harada,

Osimertinib for Epidermal Growth Factor Receptor Mutation–Positive Lung Adenocarcinoma That Transformed to T790M-Positive Squamous Cell Carcinoma Naoyuki.

Mirror Mirror on the Wall, Who Is the Fairest of Them All

EGFR delE709_T710insD: A Rare but Potentially EGFR Inhibitor Responsive Mutation in Non–Small-Cell Lung Cancer Allison Ackerman, MD, Michael A. Goldstein,

S768I Mutation in EGFR in Patients with Lung Cancer

Matthew Reichert, MD, Eric S. Bensadoun, MD

CT Features of Epidermal Growth Factor Receptor–Mutated Adenocarcinoma of the Lung: Comparison with Nonmutated Adenocarcinoma Mizue Hasegawa, MD, PhD,

Shih-Chieh Chang, Cheng-Yu Chang, Chiung-Yu Chen, Chong-Jen Yu

Multiple Pulmonary Nodules in an Elderly Woman

Compound Uncommon EGFR Mutations in a Patient with Advanced NSCLC and Durable Response to Sequential EGFR Targeted Therapies Mary Linton B Peters, MD,

T4 or MI? Journal of Thoracic Oncology Volume 6, Issue 3, (March 2011)

Maintenance Therapy and Advanced Non–Small-Cell Lung Cancer: A Skeptic's View Martin J. Edelman, MD, Thierry Le Chevalier, MD, Jean-Charles Soria, MD,

Antiangiogenesis Induced Tumor Cavitation in Lung Cancer

Ethnic Differences in the Management of Lung Cancer in New Zealand

European Lung Cancer Conference (ELCC) 2016 Organisation

Recurrent Primary Synovial Sarcoma of the Chest Wall

Trichomegaly of the Eyelashes After Treatment with Erlotinib in Non-small Cell Lung Cancer Judith Elizabeth Carser, MB, BCh, MRCR, Yvonne Jane Summers,

Tetsuzo Tagawa, MD, Miyuki Takasu, MD, Teruyoshi Ishida, MD

Metastatic Lung Cancer to the Pancreas

S-1 Treatment for Chemorefractory Thymic Carcinoma

Follow-Up of Small (4 mm or Less) Incidentally Detected Nodules by Computed Tomography in Oncology Patients: A Retrospective Review Reginald F. Munden,

Intrathoracic Desmoid Tumor: Brief Report and Review of Literature

Cristiano Rampinelli, MD, Vittoria Vecchi, MD, Massimo Bellomi, MD

Journal of Thoracic Oncology

Annemarie Becker, MD, PhD, Atie van Wijk, RN, Egbert F

David Garfield, MD Journal of Thoracic Oncology

Jamie E. Chaft, MD, Camelia S. Sima, MD, MS, Michelle S

Popcorn in the Lung Journal of Thoracic Oncology

Farhood Farjah, MD, MPH, David R. Flum, MD, MPH, Scott D

Gefitinib-Associated Propionibacterium acnes Pleural Empyema

Ana Luque, MD, Edurne Arriola, MD, PhD Journal of Thoracic Oncology

Presentation transcript:

Two Generations of Light/Never-Smokers With Advanced Adenocarcinoma of the Lung with Durable Responses to Erlotinib Nathan A. Pennell, MD, PhD, Lihong Yin, PhD, Mani Keshtgarpour, MD, Patrick C. Ma, MD Journal of Thoracic Oncology Volume 7, Issue 7, Pages 1200-1201 (July 2012) DOI: 10.1097/JTO.0b013e318250ed89 Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 A and C, CT scan of the chest in June 2008 showed bilateral mixed ground glass and solid nodules. B and D, In September 2011, after 3 years on single-agent erlotinib, the nodules had significantly reduced in size and remain stable. CT, computed tomography. Journal of Thoracic Oncology 2012 7, 1200-1201DOI: (10.1097/JTO.0b013e318250ed89) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions